BevCanna Enterprises



AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada

AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares

CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results

AbCellera Reports Q1 2021 Business Results

AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals

AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021

AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19

AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

AbCellera Reports Full Year 2020 Business Results

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients

AbCellera to Present at the SVB Leerink Global Healthcare Conference

AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer

AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19

AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call

AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19

AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%